Posaconazole
Type of Medication: Antifungal
Indications: invasive aspergillosis; serious infections caused by Scedosporium spp; Fusarium spp. or invasive Candida spp resistant to fluconazole. ABPA in conjunction with steroids
Side Effects: Gastro- intestinal disturbances ( including nausea, vomiting,abdominal pain, diarrhoea); jaundice, oedema, hypotension, chest pain, RDS, sinusitus, headache, dizziness, asthesia, anxiety, depression, confusion, agitation, hallucinations, paraesthesia, tremor: influenza like symtoms, hypoglyceamia, haematuria, blood disorders( anaemia, thrombocytopenia, leucopenia, pancytopenia), acute renal failure, hypokaleamia; visual disturbances including altered perception, blurred vision and photophobia, rash, puritus, photosensitivity, alopecia, injection site reactions. Less commonly taste disturbances, cholecystitis, pancreatitis, hepatitis, constipation, arrythmias (including QT prolongation), syncope. For further reactions see summary of product characteristics.
Route of administration: Adult (Oral)
Dose: 400 mg bd
Administration: Immediately post meal to enhance absorption. Can consider 200 mg qds dosing.
Examples of some Drug Interactions
Interacting drug: Amphoteracin
possibly antagoinse effect of amphoteracin
Interacting drug: Carbamazepine
reduces plasma concentration of voriconazole
Interacting drug: Ciclosporin
increases plasma concentration of ciclosporin
Interacting drug: Coumarins (inc warfarin)
Enhanced anticoagulant effect.
Interacting drug: Methadone
Increases plasma concentration of methadone, consider reducing dose.
Interacting drug: Omeprazole
increases plasma concentration of omeprazole – reduce dose
Interacting drug: Phenytoin
increased plasma concentration of phenytoin – monitor for signs of toxicity. Reduced plasma voriconale concentration – increase dose of voriconazole.
Interacting drug: Pimozide
increased risk of ventricular arrythmias
Interacting drug: Primadone
reduces plasma concentration of voriconazole – avoid concomitant use
Interacting drug: Quetiapine
increased plasma concentration of quetiapine – reduce dose
Interacting drug: Quinidine
increases plasma concentration of quinidine – increased risk of ventricular arrythmias avoid cincomitant use.
Interacting drug: Rifabutin
rifabuitin plasma concentration increased- monitor for signs of toxicity, voriconazole plasma conc decreased, increase dose of voriconazole.
Interacting drug: Rifampicin
plasma concentration of voriconazole reduced – avoid concomitant use.
Interacting drug: Sirolimus
increases plasma concentration of sirolimus – avoid concomitant use.
Interacting drug: Sulphonylureas
increased plasma concentration of sulphonylureas.
Interacting drug: Tacrolimus
increases plasma concentration of tacrolimus